Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus

F.�M. Wouters, Emiel; Bredenbröker, Dirk; Teichmann, Peter; Brose, Manja; F. Rabe, Klaus; M. Fabbri, Leonardo; Göke, Burkhard

doi:10.1210/jc.2011-2886

Public

Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus

Published in The Journal of Clinical Endocrinology & Metabolism • Jun 22, 2012

Authors:

Emiel F.�M. Wouters

Dirk Bredenbröker

Peter Teichmann

Abstract

CONTEXT: The phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory treatment for severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of frequent exacerbations. In previous clinical studies, a transient and reversible weight de...

Subject

Roflumilast

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!